Aura Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aura Biosciences, Inc. on May 4, 2026, covering events occurring on April 30, 2026. The Company is a Delaware corporation with principal executive offices in Boston, Massachusetts, and its common stock trades on The Nasdaq Global Market under the symbol "AURA."
Key Financial Metrics and Liquidity
The filing provides preliminary, unaudited liquidity data as of March 31, 2026, and details a significant capital transaction structure.
- Liquidity: Preliminary estimates indicate cash, cash equivalents, and marketable securities totaled approximately $114.7 million as of March 31, 2026.
- Capital Transaction: The Company entered into a Repurchase Agreement to buy back up to 6,922,870 shares of common stock held by Matrix Capital Management Master Fund, LP ("Matrix").
- Transaction Price: The repurchase price is set at $5.64 per share, matching the price of a concurrent underwritten equity offering announced on May 4, 2026.
- Funding Source: The repurchase will be funded using net proceeds from the equity offering in excess of $200 million.
- Ownership Impact: Prior to the transaction, Matrix held approximately 10.8% of the Company's outstanding common stock.
Material Changes
The primary material change is the entry into a definitive agreement to repurchase a significant block of shares from a major shareholder. This transaction is contingent upon the successful closing of the separate equity offering. If completed, the repurchased shares will become authorized but unissued shares, reducing the total outstanding share count held by Matrix to zero.
Outlook, Risks, and Contingencies
Management has outlined several conditions and risks associated with the proposed transactions:
- Contingencies: The stock repurchase is conditioned upon the closing of the equity offering and the satisfaction of other customary closing conditions. The closing is expected no earlier than two business days after the equity offering closes.
- Forward-Looking Statements: The Company explicitly states it cannot provide assurance that the repurchase will occur on the described terms or at all.
- Unaudited Data: The liquidity figure of $114.7 million is preliminary and may differ after the completion of accounting procedures for the quarter ended March 31, 2026.
- Approval: The transaction was reviewed and approved by the Audit Committee and the Board of Directors.
Investor Verification Checklist
- Verify the final closing of the underwritten equity offering announced on May 4, 2026, and the actual net proceeds generated.
- Confirm whether the net proceeds from the equity offering exceeded the $200 million threshold required to fund the repurchase.
- Monitor the official closing of the stock repurchase transaction with Matrix Capital Management.
- Review the upcoming Form 10-Q for the quarter ending June 30, 2026, for the audited cash position and the full text of the Repurchase Agreement.
- Check for any updates regarding the final share count and ownership percentage of Matrix post-transaction.